Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Launched by HELSE STAVANGER HF · Oct 18, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called central serous chorioretinopathy (CSC), which affects the eye and can cause vision problems. Researchers want to learn more about how blood flows in the eye by using special imaging techniques. They will look at both acute CSC (which is recent and lasts less than four months) and chronic CSC (which has lasted longer than four months). The goal is to understand the differences in blood flow in these two types of CSC.
To participate in this study, you need to be between 65 and 74 years old and able to give your consent to join. You should have either acute CSC with certain symptoms or chronic CSC that has been affecting your vision for some time. Participants will undergo various non-invasive eye imaging tests, and your eye health will be monitored throughout the study. It’s important to note that people with other serious eye conditions may not be eligible for this trial. If you're interested in learning more or think you might qualify, please reach out for additional information.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:-
- • Able to sign informed consent
- • Possible to obtain fundus imaging
- * Acute CSC ˂4 months of duration in one eye, defined as:
- • 1. Subfoveal presence of SRF on OCT
- • 2. Present attack is 1st -3rd attack of CSC
- • b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT
- * Chronic CSC ≥4 months of duration in one eye, defined as:
- • 1. Subfoveal presence of SRF on OCT
- • 2. Subjective visual loss/symptoms
- • 3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT
- • 4. Patient history and examination consistent with chronic CSC
- Exclusion Criteria:
- • History of retinal disease other than CSC (e.g. retinal detachment)
- • Contraindications for FA, ICGA or PDT (only for chronic CSC)
About Helse Stavanger Hf
Helse Stavanger HF is a leading healthcare organization based in Norway, dedicated to providing high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, Helse Stavanger HF focuses on innovative therapeutic interventions across various medical fields, aiming to enhance patient care and outcomes. With a commitment to ethical research practices and collaboration with academic institutions, the organization plays a vital role in the development of new treatments and the improvement of healthcare standards in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stavanger, , Norway
Patients applied
Trial Officials
Vegard Forsaa, MD PhD
Principal Investigator
Helse Stavanger HF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials